Our CORE values set us apart from other CROs, they are the heart of our company and influence everything we do. Commitment, Ownership, Responsibility and Excellence.
Our success depends on your satisfaction with our services, from providing the best advice for your needs to submitting the highest quality clinical data. Our CORE company principles lie at the heart of everything we do, and strengthen the lasting and trusting relationships that we value with all of our partners.
It’s important that all of our staff take these values into their personal belief system, to guide their professional behaviour with resulting benefits not only for themselves, but also their colleagues and, of course, our partners.
Combining a passion for people, extensive expertise and the tenacity to innovate, PCG is not just another CRO. It’s a place where CRO knowledge meets technological prowess.
Pharma Consulting Group was founded in 2003 by two Swedes, Sverre Bengtsson and Henrik Blombergsson, who were frustrated with the industry’s inefficient workflows. They developed the internationally renowned Viedoc™ EDC system, which has now been used in over 900 trials in 64 countries worldwide.
Since then, the company has evolved into its two separate entities, PCG Clinical Services and PCG Solutions, which focus respectively on delivering excellence in services and technology for clinical studies.
We provide a wide range of clinical services, from Advisory and Project Management, through to Clinical Operations, EDC, Biometrics, Data Management, Medical Writing, QA, Auditing and Validation. These capabilities are all supported by our commitment to excellence. You can rely on us to deliver high quality and effective studies, on time.
PCG - The Way Ahead.
It all started with Henrik Blombergsson and Sverre Bengtsson, two experienced CRO professionals that grew tired of the outdated workflows of their industry. They took matters in their own hands by founding PCG, or Pharma Consulting Group, in their hometown of Uppsala, Sweden in 2003.
After receiving the first assignments from local biotech companies, the PCG team quickly realised that present EDC systems were outdated, resulting in time-consuming processes that shouldn't be necessary with 21st century technology. There simply wasn't a good enough solution on the market, so they decided to design their own, and Viedoc was born. Shortly thereafter, Claude Marcus became the first client to ever try the system. He's been with the firm since.
The firm quickly grew to seven employees and became the first company in the world to get approved following the new EU Clinical Trials Directive. Assignments within biometrics were accompanied by the first clinical operations and PCG started exploring the opportunities for international establishment.
The offices were becoming too small as the company grew to 14 employees, with 50 studies and 500 active sites.
Word of PCG's revolutionary Viedoc platform was travelling fast. PCG gained its first client outside Sweden and started looking at international expansion to Japan.
The company grew to 25 employees and began its international division with emphasis on Japan.
PCG was awarded with the "Gazelle" award by Dagens Industri (Sweden's largest business paper), celebrating the company's stable growth over the previous four years. In addition, a global contract was signed with Pfizer and PGC was formally established in Japan.
PCG moved into its new, 1000 sqm headquarters in Uppsala, Sweden.
With the release of the highly anticipated Viedoc 4 just around the corner, the future was looking more promising than ever. With 50 employees and activity in over 50 countries, PCG welcomed CEO Karin Meyer to lead global operations. As the company was at its most exciting phase, the system development and consultancy divisions were incorporated individually to enhance focus and stimulate growth.
The number of employees exceeded 60 and Andy Babington took over as the new CEO.
As part of PCG’s continued progression and ambitious plans for expansion, a new company website was released. PCG’s number of studies and sites exceeded 650 and 9000 respectively. The rest is history in the making…
We believe in teamwork, and we are proud to have an excellent management team with key expertise in all required fields of the clinical trial process.
Andy joined PCG Clinical Services in September 2013. Andy has over 18 years of experience in the Pharma/CRO field. Prior to entering the Life Science industry, Andy was a professional cricketer in the UK. Andy has previously worked for major global CROs holding positions of Vice President Business Development EU and Asia. Andy has extensive experience working in EU, India and Asia.
Caroline joined PCG Clinical Services in August 2013. Caroline has broad experience within clinical research, spanning bioanalysis and medical writing to global project and portfolio management, and alliance management. Caroline has a PhD in Biochemistry and an MSc in Pharmacy from Uppsala University, Sweden.
Sverre Bengtsson is one of our founders and has served as a member of our board of directors since our inception in March 2003. Sverre holds an MBA from the University of Gothenburg, Sweden, and has more than 20 years of experience in clinical research.
Kerstin is Co-owner and joined PCG Clinical Services in January 2006. She has a PhD in Epidemiology and Biostatistics from the Karolinska Institute in Stockholm, where she later became Associate Professor. Kerstin also has a BSc in Statistics, Mathematics and Numerical Analysis from Uppsala University in Sweden. Kerstin has conducted, reviewed and analysed hundreds of studies and has collaborated with a number of companies to report statistical data for the FDA, EMA, MHRA, and the Swedish Medical Products Agency (MPA).
Jonas has over 15 years’ experience in developing organisations, teams and employees from an operational and strategic HR-perspective. Jonas joined PCG in September 2015.
Gunnar has a BSc in Natural Science and almost 40 years’ experience in Clinical Research. Gunnar served as a renowned GCP Inspector for the Swedish MPA for over 10 years, and has a wealth of experience from the Pharmaceutical industry in terms of quality management, electronic systems, data management, and clinical design and conduct. Gunnar is a key advisory resource and he helps to design studies in the most effective way, meeting regulatory requirements.
Anders has an MSc (Pharm), PhD, in Biopharmaceutics and is one of Sweden’s most experienced people in the design of clinical trials. He is Associate Professor of Clinical Drug Development Sciences at Uppsala University and has gained profound knowledge from his previous positions, which included adjunct Professor of Clinical Trial Methodology, Uppsala University, and Director of Clinical Pharmacology at the Swedish MPA. During his time as Chief Scientific Officer at Quintiles Nordic Operations, Anders oversaw more than 300 clinical trials. Anders is an instrumental resource to assist clients in the early phases of study design and can help ensure studies are on the right track from the start.
Johanna holds a PhD in toxicology and has over 16 years’ experience within research and the CRO industry, working extensively within phase I-II studies and associated project management. Johanna joined PCG Clinical Services in September 2015. She came from Quintiles where she held the position of Director Clinical Project Management.
Johannes holds an MSc. in Biomedicine from Uppsala University in Sweden. He joined PCG Clinical Services in 2007 and has managed projects across all phases, with a primary focus on Viedoc EDC.
Sandra joined PCG Clinical Services in 2012 and has broad experience of clinical research with a focus on medical and scientific writing, and project management. Sandra has a PhD in Biology and an MSc in Mathematics and Natural Sciences from Uppsala University, Sweden.
Daniel joined PCG Clinical Services in 2014. Since 2007, he has gained experience of all phases of clinical trials, with particular focus on clinical monitoring and project management, through working for several CROs and a pharmaceutical company. Daniel has an MSc in Biomedicine from Uppsala University, Sweden.